Market Overview

Citi Launches Positive Coverage On Five Prime Therapeutics

Share:
Citi Launches Positive Coverage On Five Prime Therapeutics
Related FPRX
10 Biggest Price Target Changes For Monday
The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait

Citi’s Robyn Karnauskas believes Five Prime Therapeutics Inc (NASDAQ: FPRX) has a trifecta of factors in its favor, including its “hot” immunoncology (I/O) target, a solid partner in Bristol-Myers Squibb Co (NYSE: BMY) and strong platform technology.

Karnauskas initiated coverage of Five Prime with a Buy rating and price target of $65.

Multiple Catalysts

The analyst believes the company has “multiple shots on goal in various cancers,” as well as a promising lead drug in Cabiralizumab, compelling data from FPA144 in gastric cancer, which provides valuation support and “unique platform technology validated by multiple collaborations.”

Related Link: JMP Securities Downgrades Ariad, Cites Limited Near-Term Upside In Light Of Prescription Trends

Karnauskas said as combo data with Opdivo becomes available for Cabira in 2017, investors would be able to assign a higher value to the program and there could be potential upside of 35–65 percent to the stock valuation.

Cabira Potential

“All major I/O developers are testing checkpoint combos with CSF-1R and those data should also help validate mechanism” for Cabira, the analyst pointed out.

Karnauskas expects Cabira to achieve peak sales of $800 million, with upside due to the I/O opportunity.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for FPRX

DateFirmActionFromTo
Sep 2018Leerink SwannReinstatesOutperform
Aug 2018CitigroupMaintainsBuyBuy
Aug 2018WedbushMaintainsNeutralNeutral

View More Analyst Ratings for FPRX
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Health Care Initiation Analyst Ratings Trading Ideas General Best of Benzinga

 

Related Articles (BMY + FPRX)

View Comments and Join the Discussion!

Citing Rising Risk Of Default, Argus Downgrades Tidewater To Sell

Live Cattle Futures Little Higher